Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 33.19 Million USD | -7.78% |
| 2022 | 35.99 Million USD | -91.44% |
| 2021 | 420.55 Million USD | 7.74% |
| 2020 | 390.33 Million USD | 3.92% |
| 2019 | 375.61 Million USD | 14.01% |
| 2018 | 329.46 Million USD | 1380.2% |
| 2017 | 22.25 Million USD | 434.41% |
| 2016 | 4.16 Million USD | -42.06% |
| 2015 | 7.18 Million USD | -73.32% |
| 2014 | 26.94 Million USD | -21.65% |
| 2013 | 34.39 Million USD | 210.18% |
| 2012 | 11.08 Million USD | -51.18% |
| 2011 | 22.71 Million USD | -69.72% |
| 2010 | 75 Million USD | 0.0% |
| 2009 | 75 Million USD | 0.0% |
| 2008 | 75 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 32.99 Million USD | 0.0% |
| 2024 Q3 | 28.92 Million USD | 0.0% |
| 2024 Q2 | 30.29 Million USD | 0.0% |
| 2023 FY | 33.19 Million USD | -7.78% |
| 2023 Q1 | 36.51 Million USD | 1.43% |
| 2023 Q3 | 33.84 Million USD | -0.98% |
| 2023 Q2 | 34.17 Million USD | -6.39% |
| 2023 Q4 | 33.19 Million USD | -1.91% |
| 2022 Q3 | 36.02 Million USD | -2.84% |
| 2022 FY | 35.99 Million USD | -91.44% |
| 2022 Q1 | 440.27 Million USD | 4.69% |
| 2022 Q2 | 37.08 Million USD | -91.58% |
| 2022 Q4 | 35.99 Million USD | -0.08% |
| 2021 FY | 420.55 Million USD | 7.74% |
| 2021 Q3 | 412.04 Million USD | 1.36% |
| 2021 Q2 | 406.52 Million USD | 3.03% |
| 2021 Q1 | 394.57 Million USD | 1.09% |
| 2021 Q4 | 420.55 Million USD | 2.06% |
| 2020 Q3 | 406.33 Million USD | 1.12% |
| 2020 FY | 390.33 Million USD | 3.92% |
| 2020 Q1 | 380.03 Million USD | 1.18% |
| 2020 Q2 | 401.83 Million USD | 5.74% |
| 2020 Q4 | 390.33 Million USD | -3.94% |
| 2019 Q2 | 364.74 Million USD | 1.0% |
| 2019 Q1 | 361.13 Million USD | 9.61% |
| 2019 Q3 | 368.41 Million USD | 1.01% |
| 2019 FY | 375.61 Million USD | 14.01% |
| 2019 Q4 | 375.61 Million USD | 1.95% |
| 2018 Q4 | 329.46 Million USD | 1.17% |
| 2018 Q3 | 325.66 Million USD | 1.16% |
| 2018 FY | 329.46 Million USD | 1380.2% |
| 2018 Q2 | 321.92 Million USD | 1.16% |
| 2018 Q1 | 318.22 Million USD | 1329.71% |
| 2017 Q4 | 22.25 Million USD | -1.96% |
| 2017 Q3 | 22.7 Million USD | 1442.26% |
| 2017 Q2 | 1.47 Million USD | -55.53% |
| 2017 Q1 | 3.31 Million USD | -20.53% |
| 2017 FY | 22.25 Million USD | 434.41% |
| 2016 FY | 4.16 Million USD | -42.06% |
| 2016 Q1 | 5.62 Million USD | -21.73% |
| 2016 Q3 | 5.77 Million USD | 1.28% |
| 2016 Q4 | 4.16 Million USD | -27.84% |
| 2016 Q2 | 5.69 Million USD | 1.28% |
| 2015 Q1 | 11.7 Million USD | -56.55% |
| 2015 FY | 7.18 Million USD | -73.32% |
| 2015 Q4 | 7.18 Million USD | -10.89% |
| 2015 Q3 | 8.06 Million USD | -7.92% |
| 2015 Q2 | 8.76 Million USD | -25.16% |
| 2014 Q1 | 28.35 Million USD | -17.55% |
| 2014 FY | 26.94 Million USD | -21.65% |
| 2014 Q4 | 26.94 Million USD | 1.7% |
| 2014 Q3 | 26.49 Million USD | -7.58% |
| 2014 Q2 | 28.67 Million USD | 1.1% |
| 2013 Q3 | 60.17 Million USD | 1.82% |
| 2013 Q4 | 34.39 Million USD | -42.85% |
| 2013 Q1 | 7.97 Million USD | -28.08% |
| 2013 FY | 34.39 Million USD | 210.18% |
| 2013 Q2 | 59.1 Million USD | 641.07% |
| 2012 Q2 | 17.06 Million USD | -14.38% |
| 2012 Q3 | 14.11 Million USD | -17.26% |
| 2012 Q4 | 11.08 Million USD | -21.45% |
| 2012 FY | 11.08 Million USD | -51.18% |
| 2012 Q1 | 19.92 Million USD | -12.26% |
| 2011 FY | 22.71 Million USD | -69.72% |
| 2011 Q3 | 86 Million USD | 0.0% |
| 2011 Q4 | 22.71 Million USD | -73.59% |
| 2010 FY | 75 Million USD | 0.0% |
| 2010 Q4 | 75 Million USD | 0.0% |
| 2010 Q3 | 75 Million USD | 0.0% |
| 2009 FY | 75 Million USD | 0.0% |
| 2009 Q4 | 75 Million USD | 0.0% |
| 2008 FY | 75 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 51.26 Million USD | 35.241% |
| Harrow Health, Inc. | 183.17 Million USD | 81.877% |
| Dynavax Technologies Corporation | 252.41 Million USD | 86.849% |
| Biofrontera Inc. | 804 Thousand USD | -4028.856% |
| Cronos Group Inc. | 1.55 Million USD | -2029.314% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -38056.322% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 93.338% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 2.907% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -7195.824% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -159.665% |
| Radius Health, Inc. | 339.66 Million USD | 90.227% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| DURECT Corporation | 2.7 Million USD | -1128.571% |
| ProPhase Labs, Inc. | 10.25 Million USD | -223.611% |
| Safety Shot Inc | 304.9 Thousand USD | -10787.254% |
| Phibro Animal Health Corporation | 458.28 Million USD | 92.757% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -28241.401% |
| Alvotech | 1.02 Billion USD | 96.77% |
| Assertio Holdings, Inc. | 38.51 Million USD | 13.808% |
| Rockwell Medical, Inc. | 8.29 Million USD | -300.289% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -6058.413% |
| Procaps Group S.A. | 28.41 Million USD | -16.846% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -149.107% |
| SCYNEXIS, Inc. | 12.15 Million USD | -173.016% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -205.194% |
| Viatris Inc. | 16.18 Billion USD | 99.795% |
| OptiNose, Inc. | 611 Thousand USD | -5333.061% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -9780.027% |
| Tilray Brands, Inc. | 287.93 Million USD | 88.471% |
| PetIQ, Inc. | 437.82 Million USD | 92.418% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -6058.413% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 87.148% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 64.48 Million USD | 48.525% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 93.225% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -24473.429% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 45.352% |
| Journey Medical Corporation | 14.62 Million USD | -127.028% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -384.093% |
| Alpha Teknova, Inc. | 13.25 Million USD | -150.517% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -4510.556% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 72.454% |
| PainReform Ltd. | 30 Thousand USD | -110553.333% |
| Cosmos Health Inc. | 3.03 Million USD | -993.65% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1.331% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -408.206% |
| Embecta Corp. | 1.62 Billion USD | 97.958% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 93.539% |
| Incannex Healthcare Limited | 210 Thousand USD | -15707.619% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -147542.768% |
| Shineco, Inc. | 10.01 Million USD | -231.386% |
| Procaps Group, S.A. | 28.41 Million USD | -16.846% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 89.28% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 63.551% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 94.612% |
| Alvotech | 1.02 Billion USD | 96.77% |
| Hempacco Co., Inc. | 5.93 Million USD | -459.703% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 40.949% |
| Bright Green Corporation | 201.78 Thousand USD | -16351.336% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 93.381% |
| Kamada Ltd. | 7.43 Million USD | -346.303% |
| Indivior PLC | 235.66 Million USD | 85.914% |
| Evoke Pharma, Inc. | 5 Million USD | -563.92% |
| Flora Growth Corp. | 942 Thousand USD | -3423.992% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -147542.768% |
| Evolus, Inc. | 120.35 Million USD | 72.419% |
| HUTCHMED (China) Limited | 48.18 Million USD | 31.113% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 94.366% |
| Akanda Corp. | 2.49 Million USD | -1229.353% |